Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients

* Age ≥ 18 years old * ECOG performance status ≤ 1 * Must have histologically or cytologically confirmed tumour, eligible for treatment with ICI as standard-of-care alone or in combination with another ICI, ICI with chemotherapy, ICI with radiotherapy, or ICI with targeted therapy with no restrictions on number of prior systemic therapies * Adequate bone marrow function as defined below * Absolute neutrophil count ≥ 1500/µL or 1.5x109/L * Hemoglobin ≥ 9 g/dL * Platelets ≥ 100000/µL or 100x109/L * Adequate liver function as defined below * Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome \< 3xUNL is allowed * AST (SGOT)/ALT (SGPT) ≤ 3.0 x ULN * Alkaline phosphatase ≤ 3.3 x ULN * Adequate renal function as defined below \_- Creatinine ≤ 1.5 x UNL or creatinine clearance \> 60 mL/min * Patient monitored for their cancer at CHU of Brest * Did not oppose for their samples and clinical data to be used for translational research * Non-opposition form obtained prior to any study related procedure Exclusion Criteria: * Patient with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study * Patient already receiving ICI * Primary immunodeficiency and/or history of allogenic transplantation * Current active infection * Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection) * Subject of guardianship (tutorship, curatorship) * Active pregnancy